

SUREmAb™

**Monoclonal Antibody Development,
the Way it's Meant to Be**

Simple, secure, and streamlined from cell line development (CLD) to drug substance release

SUREmAb™ preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 10 g/L) with a streamlined, lower-cost workflow. Thanks to this preset offer, your simple mAb development is made SURE, while accelerating timelines and maximizing ROI.



Efficient processes for high titers and exceptional yield



Drug substance release in as little as 11 months



Transfection to high-performing RCB in as little as 9 weeks



Innovation with alleviation of royalties when you manufacture with KBI Biopharma

Join a Legacy of Success

SUREmAb™ is built on the power of our SUREtechnology Platform™ powered by Selexis®

15+

Years of mAb Development Experience


150+

Therapeutic mAb Projects

7

Commercialized mAb Therapeutics

SUREmAb™: Research Cell Bank (RCB) Generation, Simplified



SUREmAb™: Transition to Manufacturing, Streamlined





Figure 1: SUREmAb™ provides similar performance to regular SUREtechnology Platform™ process

Fig. 1 - SUREmAb™ compared to regular SUREtechnology Platform™ process. Titer profile of twelve ROB cell lines expressing an IgG1 produced in Ambr® 15 using SUREmAb™ platform in blue and SUREtechnology Platform™ in orange. Straight line represents the average value and the bands represent the SD of the twelve ROB cell lines.

Figure 2: SUREmAb™ provides robust cell lines shown to be scalable

Fig. 2 - SUREmAb™ scalability. VCD, viability (a) and productivity (b) profiles of one stable ROB expressing an IgG1 in 3 different scales: Ambr® 15, 3L and 200L bioreactors. Two chemically defined media were used: standard industry medium 1 (straight lines) and CHO-optimized medium CELLIST™ Basal CHO MX (dotted line).



Global Compliance Local Presence



Scan the code to learn more about SUREmAb™

Please note: The SUREmAb offer does not apply to mAb-based biosimilar projects or for any IgG shape-derived proteins that are different from an intact IgG format - including bsAbs, Fc fusions, and IgG fragments - as well as other protein classes outside of IgGs. Timeline estimates are subject to open manufacturing capacity and may vary by project.



A JSR Life Sciences Company

